Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 54

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 54
---
 of our executive officers with those of our stockholders by incentivizing and rewarding achievement of business objectives that we believe will enhance our value and by promoting commitment to long-term success. Our current executive compensation program primarily includes (1) base salary, (2) annual performance-based incentive compensation, and (3) long-term incentive compensation exclusively in the form of stock options with the goal of aligning the long-term interests of executive officers with those of our stockholders and otherwise encouraging the achievement of superior results over an extended time period. Our Board and the Compensation Committee reviews our compensation plans and programs on an ongoing basis and periodically make adjustments taking into account competitive conditions and other factors. Please read the section entitled “Executive Compensation” above for additional details about our executive compensation programs, including information about the fiscal year 2024 compensation of our named executive officers. This advisory vote gives our stockholders the opportunity to approve or not approve our executive compensation programs and policies by voting on the following resolution:

“RESOLVED, that the stockholders of Daré Bioscience, Inc. approve, on an advisory basis, the compensation paid to the company’s named executive officers as disclosed in this Proxy Statement pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion.”

The vote on this proposal will not be construed to create or imply any change to the fiduciary duties of our Board, or to create or imply any additional fiduciary duties for our Board. The approval or disapproval of this proposal by our stockholders will not require our Board to take any action regarding our executive compensation practices and will not alter any contractual obligations between us and any of our executive officers or other employees.

#### OUR BOARD RECOMMENDS A VOTE “FOR” PROPOSAL 3.
2025 Proxy Statement | Page 41

#### PROPOSAL 4
<div align='center'>TO APPROVE AN AMENDMENT TO THE COMPANY'S 2022 STOCK INCENTIVE PLAN</div>

#### General
The Daré Bioscience, Inc. 2022 Stock Incentive Plan (the “2022 Plan”) was approved by our stockholders at our 2022 annual meeting of stockholders. When we solicited stockholder approval of the 2022 Plan, we stated that, depending on a variety of factors, we anticipated that the number of shares available under the 2022 Plan would be an appropriate number to satisfy our equity compensation needs for the next three years, or until 2025.

We are asking our